Learn the many ways physical therapists provide support for bleeding disorder patients....
HFM and Save One Life are partnering to support the unmet needs...
Patient organizations are in ongoing communication with manufacturer...
Last week, Bayer announced the recall of two lots of Kogenate® FS...
- Featured News
- Health Education
- Medical Advisory
HFM and Save One Life are partnering to support the unmet needs of women and girls with bleeding disorders across the world.
Last week, Bayer announced the recall of two lots of Kogenate® FS antihemophilic factor (recombinant) 2000 IU vials. That highly concerning announcement has raised many questions on the part of both national organizations and community members.
Shellye Horowitz reviews the birth of HFM’s National Conference for Women with Hemophilia and the movement to ensure women with hemophilia receive proper medical care.
As the 2019 legislative cycle begins, HFM will be monitoring the introduction of bills and assessing their possible impact on the bleeding disorders community
The bill also includes exemptions for disability caretakers, parents of children under six, pregnant women, people receiving disability benefits, and those who are medically frail, which includes patients diagnosed with hemophilia, VWD, and other factor deficiencies.
Children’s Special Health Care Services: Maintaining Access to Care for the Bleeding Disorders Community
CSHCS covers people under the age of 21 with a qualifying medical condition. However, the age limitation is waived for patients with certain blood clotting disorders (hemophilia and other bleeding disorders) and cystic fibrosis.
This legislation would require insurance plans to offer a copay only option, which would not require patients to reach a deductible before their insurance begins to pay a portion of the cost.
A few things to keep in mind! Do you depend on factor co-pay assistance? If so, you should know that some insurance plans have changed …
If you are currently using Monoclate-P®, please contact your physician or hemophilia treatment center to learn about other options that are available to you for treatment.
The Company has suspended dosing in all ongoing fitusiran studies pending further review of the safety event and development of a risk mitigation strategy.